PRMA Consulting

@prmaconsulting

Accelerating market access with unique digitally enabled consultancy.

United Kingdom
Vrijeme pridruživanja: ožujak 2013.

Tweetovi

Blokirali ste korisnika/cu @prmaconsulting

Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @prmaconsulting

  1. "Drug Quality: FDA officials discuss perceptions" via

    Poništi
  2. New at CADTH: updated review process, economic methods, and submission requirements >>

    Poništi
  3. HAS presents its action plan for the evaluation of innovative medicines >>

    Poništi
  4. Orphan drug re-assessments in Germany: the impact on additional benefit and price >>

    Poništi
  5. Poništi
  6. Enable affiliates to focus on impactful local activities by auto-populating up to 80% of their draft submissions >>

    Poništi
  7. "Failed pivotal study? You can still have breakthrough therapy status — FDA signals to Resverlogix" via

    Poništi
  8. How new provides an improved framework for real-time decision-making in >>

    Poništi
  9. 4. velj

    Championing digital transformation within biotech and pharma companies >> A day in the life of a Client Excellence Manager

    Poništi
  10. 4. velj

    "Viraj Narayanan discusses the impacts of real-world data on clinical research" via

    Poništi
  11. 4. velj

    Enable affiliates to focus on impactful local activities by auto-populating up to 80% of their draft submissions >>

    Poništi
  12. 4. velj

    Digital innovation news: Helping clients overcome the challenges of creating simultaneous, high-quality submissions is just one reason why the was chosen as a finalist by a panel of HEOR and RWE experts.

    Poništi
  13. 4. velj

    "ICER finalizes 2020 updates to methods and public meeting procedures for value assessment framework" via

    Poništi
  14. 4. velj

    "The 10 most-anticipated drug launches of 2020" via

    Poništi
  15. 4. velj

    "Biologic and biosimilar misinformation: FDA drafts guidance" via

    Poništi
  16. 4. velj

    High-cost combinations >> Will the scale of high-cost combinations coming to market force a significant change in pricing and reimbursement policies?

    Poništi
  17. 3. velj

    The role of the patient voice in market access >> Exploring the evolution of in .

    Poništi
  18. 3. velj

    "HTA around the world: broadening our understanding of cross-country differences" via

    Poništi
  19. 3. velj

    Four recommendations to kick-start the of your processes >>

    Poništi
  20. 3. velj

    "5 years of biosimilars in the US: what have we learned?" via

    Poništi

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·